3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
209
Neoplasms
119
Breast Neoplasms
113
Colorectal Neoplasms
100
Prostatic Neoplasms
80
Ovarian Neoplasms
79
Neoplasm Metastasis
79
Lung Neoplasms
70
Multiple Myeloma
67
Squamous Cell Carcinoma of Head and Neck
51
Pancreatic Neoplasms
50
Endometrial Neoplasms
50
Recurrence
48
Stomach Neoplasms
41
Melanoma
41
Leukemia, Lymphocytic, Chronic, B-Cell
41
Carcinoma, Renal Cell
40
Small Cell Lung Carcinoma
39
Leukemia, Myeloid, Acute
35
Urinary Bladder Neoplasms
32
Lymphoma, Non-Hodgkin
32
Parkinson Disease 4, Autosomal Dominant Lewy Body
30
Triple Negative Breast Neoplasms
29
Carcinoma, Hepatocellular
28
Head and Neck Neoplasms
27
Advanced Solid Tumors
27
Lymphoma, Large B-Cell, Diffuse
26
Lymphoma, Follicular
25
Esophageal Neoplasms
24
Lymphoma
23
Interventions
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Biochemically Recurrent Prostate Cancer
×
30 days
×
Clear all
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled